Myocyte Enhancer Factor 2D Protéines (MEF2D)

MEF2D is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. De plus, nous expédions MEF2D Anticorps (158) et et beaucoup plus de produits pour cette protéine.

afficher tous les protéines Gène GeneID UniProt
MEF2D 4209 Q14814
MEF2D 17261  
MEF2D 81518 O89038
Comment commander chez anticorps-enligne
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Commandez enligne
  • orders@anticorps-enligne.fr

Top MEF2D Protéines sur anticorps-enligne.fr

Showing 5 out of 6 products:

Catalogue No. Origin Source Conjugué Images Quantité Livraison Prix Détails
Cellules d'insectes Humain His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 60 Days
$9,626.73
Détails
Cellules d'insectes Souris His tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 1 mg 60 Days
$9,626.73
Détails
Wheat germ Humain GST tag 10 μg 11 to 12 Days
$340.00
Détails
HEK-293 Cells Humain Myc-DYKDDDDK Tag Validation with Western Blot 20 μg 11 Days
$888.80
Détails
Levure Rat His tag   1 mg 60 to 71 Days
$3,439.33
Détails

MEF2D Protéines protéines par origine et source

Origin Exprimée danse Conjugué
Human , ,
, ,
Mouse (Murine)

Rat (Rattus)

Plus protéines pour Myocyte Enhancer Factor 2D (MEF2D) partenaires d'interaction

Human Myocyte Enhancer Factor 2D (MEF2D) interaction partners

  1. Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation

  2. MEF2D variant associated with SLE affects MEF2D gene regulation and splicing.

  3. Novel insights into the mechanisms underlying leukemia development by MEF2D fusion genes and the involvement of the deregulation of miRNA-mediated repression in cancer development.

  4. Our study suggests that the MEF2D, PRDM16 and ASTN2 genes from GWAS are associated with migraine susceptibility, especially migraine without aura , among Chinese patients. It appears that there is no association with serotonin receptor related genes.

  5. In summary, we found that miR-1244 affected cisplatin-treated non-small cell lung cancer via MEF2D expression.

  6. MEF2d mRNA level is up-regulated in both sporadic and SOD1 + ALS patients.

  7. MEF2D might be a potential biomarker during chronic inflammation-lung cancer transition, predicting the risk of lung cancer among patients with chronic respiratory diseases.

  8. HIF-1alpha transactivates MEF2D expression by binding to the MEF2D gene promoter to induce angiogenesis in colorectal tumors.

  9. MEF2D directly regulated transcription of the epithelial-mesenchymal transition driver gene ZEB1 and facilitated histone acetylation at the ZEB1 promoter in colorectal cancer cells

  10. MEF2D-BCL9-positive patients had B-cell precursor immunophenotype and were characterized as being older in age, being resistant to chemotherapy, having very early relapse, and having leukemic blasts that mimic morphologically mature B-cell leukemia with markedly high expression of HDAC9.

  11. These results suggest that PPARgamma may exert its antiproliferative effects by negatively regulating the MEF2D in CM cells, which through upregulation of miR-122, and PPARgamma/miR-122/MEF2D signaling pathway may be a novel target for treatment of CM.

  12. MEF2D overexpression participated in the growth of lung cancers and its aberrant expression may result from the reduction of tumor suppressor miR-218.

  13. MEF2D is a direct target of miR-19.

  14. We found that in malignant glioma, there is an aberrantly high expression of MEF2D, which leads to poor prognosis of malignant glioma. The downregulation of MEF2D suppresses the proliferation of malignant glioma cell lines by inducing delay of S and G2/M phases of cell cycle and promoting apoptosis.

  15. MEF2D regulates IGF-1-induced proliferation and apoptosis in CM development, indicating IGF-1-MEF2D pathway may be a useful target for treatment.

  16. Pokemon was found to enhance the migration and invasion of hepatocellular carcinoma by increasing MEF2D expression

  17. miR-1244 and MEF2D form an autoregulatory loop contributing to the progression of lung carcinoma.

  18. MEF2D was also found to increase the transcription of Pokemon by binding myocyte enhancer factor 2 (MEF2) sites within its promoter region, that can promote Hepatocellular carcinoma invasion

  19. Cell cycle progression was also inhibited by MEF2D suppression.

  20. OA induced cell cycle arrest in lung cancer cells through miR-122/Cyclin G1/MEF2D pathway. This finding may contribute to the understanding of the molecular mechanism of OA's anti-tumor activity

Mouse (Murine) Myocyte Enhancer Factor 2D (MEF2D) interaction partners

  1. MEF2D and DYRK1A are coordinately expressed in mouse brain during neurodevelopment. It elucidates a new regulating mechanism of DYRK1A in embryonic brain development and further enriches the evidence of DYRK1A participation in mouse brain neurogenesis.

  2. Both synapse silencing and elimination required de novo transcription, but only silencing required the activity-dependent transcription factors MEF2A/D.

  3. In the Mef2d heterozygous retina, NRF2 is not up-regulated to a normal degree in the face of light-induced oxidative stress, contributing to accelerated photoreceptor cell death.

  4. These findings uncover a novel role for Mef2c/d in coordinating the transcriptional network that promotes early B-cell development.

  5. This study identifies MEF2D as a critical regulator of IL-10 gene expression that negatively controls microglia inflammation response and prevents inflammation-mediated cytotoxicity.

  6. Mef2d is essential for the maturation and integrity of retinal photoreceptor and bipolar cells

  7. miR-103 worked through activating AKT/mTOR signal pathway and impairing target gene MEF2D.

  8. These findings demonstrate that broadly expressed TFs acquire specific functions through competitive recruitment to enhancers by tissue-specific Mef2d and through selective activation of these enhancers to regulate tissue-specific genes.

  9. Whereas MEF2A is absolutely required for proper myoblast differentiation, MEF2B, -C, and -D were found to be dispensable for this process.

  10. A role for endogenous MEF2 factors exclusively in hormone/Fsk/cAMP-induced Nr4a1 gene expression in mouse MA-10 Leydig cells.

  11. Oxidation of survival factor MEF2D inhibits its function, underlies oxidative stress-induced neurotoxicity, and may be a part of the Parkinson disease pathogenic process.

  12. Results demonstrate that coordinated alternative splicing by a single RNA binding protein modulates transcription (Mef2d) and cell signaling (Rock2) programs to drive tissue-specific functions (cell fusion) to promote a developmental transition.

  13. We found that Parkinson's disease -associated neurotoxins destabilize MEF2D mRNA and reduce its level in vitro and in vivo.

  14. Combined deletion of the Mef2a, c, and d genes results in a blockade to muscle regeneration.

  15. The resultsof this study showed that MEF2D is a substrate for phosphorylation by ATM, thus promoting survival in response to DNA damage.

  16. This study identified lysine-267 as a methylation/demethylation site and demonstrated that the lysine methylation state of MEF2D regulates its transcriptional activity and skeletal muscle cell differentiation.

  17. results reveal a novel mechanism in which a tissue-specific alternate splicing event has evolved that permits a ubiquitously expressed transcription factor, Mef2d, to escape inhibitory signaling for temporal regulation of gene expression

  18. the inactivation of Nur77, induced by loss of MEF2 activity, plays a critical role in nigrostriatal degeneration in vivo

  19. Expression of myogenin is regulated, at least in part, by the decreased glycosylation-dependent recruitment of Mef2D to the promoter region, and this is one of the negative regulatory mechanisms of skeletal myogenesis by O-GlcNAc glycosylation.

  20. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.

Cow (Bovine) Myocyte Enhancer Factor 2D (MEF2D) interaction partners

  1. Expression analysis showed that the MEF2D polymorphisms were highly correlated with MEF2D mRNA and protein levels in the longissimus dorsi muscle of Polish Holstein-Friesian bulls carrying the three different combined genotypes.

Profil protéine MEF2D

Profil protéine

This gene is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Members of this family are involved in control of muscle and neuronal cell differentiation and development, and are regulated by class II histone deacetylases. Fusions of the encoded protein with Deleted in Azoospermia-Associated Protein 1 (DAZAP1) due to a translocation have been found in an acute lymphoblastic leukemia cell line, suggesting a role in leukemogenesis. The encoded protein may also be involved in Parkinson disease and myotonic dystrophy. Alternative splicing results in multiple transcript variants.

Gene names and symbols associated with MEF2D

  • myocyte enhancer factor 2D (mef2d)
  • myocyte enhancer factor 2D (MEF2D)
  • MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D) (MEF2D)
  • myocyte enhancer factor 2D (Mef2d)
  • C80750 Protéine
  • MGC145245 Protéine
  • sl-1 Protéine
  • sl1 Protéine
  • XMEF2D Protéine

Protein level used designations for MEF2D

myocyte enhancer factor 2D , MADS box transcription enhancer factor 2, polypeptide D (myocyte enhancer factor 2D) , myocyte-specific enhancer factor 2D-like , MADS box transcription enhancer factor 2, polypeptide D , myocyte-specific enhancer factor 2D

GENE ID SPECIES
780389 Xenopus (Silurana) tropicalis
100023326 Monodelphis domestica
100406906 Callithrix jacchus
100459204 Pongo abelii
769067 Gallus gallus
4209 Homo sapiens
17261 Mus musculus
81518 Rattus norvegicus
490413 Canis lupus familiaris
100156714 Sus scrofa
100336730 Bos taurus
Fournisseurs de qualité sélectionnés pour MEF2D Protéines (MEF2D)
Avez-vous cherché autre chose?